Technology Overview
%C2%A0.jpg)
Engineered red blood cells (eRBCs) have great potential in treating autoimmune diseases, for instance in type 1 diabetes. Carcell is developing the first therapeutic product candidate and quickly moving to CMC and scale-up production.
Carcell is developing its own proprietary lipid nanoparticles to deliver nucleic acids for a variety of applications. Lipid nanoparticles (LNPs) are clinically validated delivery vehicles that are less immunogenic than viral vectors and thus redosable. With different payload molecules, Carcell is leveraging its LNP platform to enable our collaborators to deliver their nucleic acid drugs
Carcell has a ligase, Readilase, that is capable of fast enzymatic ligation of proteins/peptides. Initially used in our E3 platform to produce eRBCs, we now seek to empower our collaborator's and client's ligation processes in view of developing a therapeutic drug or for research purposes.